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Bioluminescence imagingHuman gammaherpesvirus infections of the central nervous system (CNS) have been linked to various neu-
rological diseases. Murine gammaherpesvirus 68 (MHV-68), genetically related and biologically similar to
human gammaherpesviruses, infects the CNS in laboratory mice. However, viral persistency of MHV-68 has
not been studied following CNS infection. In this study, we undertook the noninvasive bioluminescence im-
aging of a recombinant MHV-68 expressing the ﬁreﬂy luciferase (M3FL) to monitor virus progression after
CNS infection. The M3FL virus inoculated in the brain systemically spread to the abdominal area in biolumi-
nescence imaging, which was further conﬁrmed by detection of viral genome and transcripts. The dissemi-
nated wild-type virus established latency in the spleen. Moreover, the treatment of the infected mice with
CsA induced reactivation of latent MHV-68 from the brain and the spleen. Our results suggest that MHV-68
may persist both inside and outside the CNS once it gains access to the CNS.
© 2011 Elsevier Inc. All rights reserved.Introduction
Murine gammaherpesvirus (MHV-68 or γHV-68) is genetically relat-
ed and biologically similar to human gammaherpesviruses, Epstein–Barr
virus (EBV) and Kaposi's sarcoma-associated herpesvirus (Virgin et al.,
1997).MHV-68 can infect laboratorymicewith an amenable genetic sys-
tem, thereby providing a tractable animal model in which to study gam-
maherpesvirus pathogenesis and persistent infection in vivo (Simas and
Efstathiou, 1998; Virgin and Speck, 1999). Although gammaherpes-
virusesmainly infect and establish latency in lymphocytes, accumulating
evidence suggests the possible neurotropism or neuroinvasiveness of
human gammaherpesviruses (Chan et al., 2000; Chan et al., 1999;
Karatas et al., 2008;Weinberg et al., 2005) and their involvement in var-
ious neurological diseases such as aseptic meningitis, encephalitis, HIV-
related primary CNS lymphoma, and multiple sclerosis (Bossolasco
et al., 2006; Said et al., 1997; Seraﬁni et al., 2007). Neurological complica-
tions are cited as the leading cause of death resulting from infectious
mononucleosis caused by EBV (Hoover et al., 2004).
Consistent with this notion, intranasal (i.n.) infection of newborn
mice with MHV-68 led to cerebral infection with inﬂammation,
which closely mirrors CNS infection of EBV (Hausler et al., 2005). In
addition, intracerebral inoculation of MHV-68 resulted in successful
replication in the brains of mice younger than 4 weeks of age, which
were all succumbed to deaths by 7 days post-infection (Terry et al.,rights reserved.2000). Our recent study showed that most mice at 9 to 10 weeks of
age were alive following intracerebroventricular (i.c.v.) infection of
MHV-68 with the survival rate of ~80% due to differential expression
of proinﬂammatory cytokines, suggesting age-dependent pathogene-
sis of MHV-68 in the brain (Cho et al., 2009). However, it remains to
be determined whether the virus can persist in the host upon cerebral
infection and if so, where the virus establishes persistent infection. To
address these questions, we undertook bioluminescence imaging of
MHV-68 infection using a recombinant MHV-68 (M3FL) expressing
ﬁreﬂy luciferase driven by the lytic M3 promoter (Hwang et al.,
2008; Milho et al., 2009). The bioluminescence imaging technique
has proven to be a valuable tool to study dynamic interactions be-
tween MHV-68 and the host, leading to identiﬁcation of replication
kinetics and novel sites for in vivo virus replication (Hwang et al.,
2008; Milho et al., 2009). Here we show the systemic spread of
MHV-68 following CNS infection and subsequent establishment of la-
tency in the spleen. Furthermore, treatment with an immunosuppres-
sive drug induced reactivation of the latent virus from the brain as
well as from the spleen, suggesting that MHV-68 may persist inside
the brain in addition to the spleen.
Results
Systemic spread of MHV-68 following inoculation in the brain
To non-invasively investigate viral persistency of MHV-68 upon
cerebral infection, we used a recombinant MHV-68 (M3FL) that ex-
presses the ﬁreﬂy luciferase under the M3 lytic viral promoter. The
24 H.-R. Kang et al. / Virology 423 (2012) 23–29M3FL recombinant virus was previously constructed by inserting the
ﬁreﬂy expression cassette at the left end of the viral genome (nt 746)
(Hwang et al., 2008). Insertion of the reporter gene cassette had little
effect on viral productive infection in vitro and in vivo (Hwang et al.,
2008). We infected 9- to 10-week-old BALB/c mice with M3FL
(8800 pfu) via i.c.v. inoculation (n=4) or via i.p. inoculation (n=2)
as a control and monitored luciferase expression under intranasal an-
esthesia using an in vivo bioluminescence imaging system at the indi-
cated time-points (Fig. 1). Although intranasal route is commonly
used to infect MHV-68, viral inoculation via i.p. was chosen as a con-
trol to make it a simple comparison with i.c.v. for viral progression.
M3FL via i.p. inoculation was reported to replicate only in theB
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Fig. 1. In vivo bioluminescence imaging of MHV-68 after inoculation into the brain. Mice (n
indicated days. (A) Representative images are shown for in vivo productive infection at the
bar indicates the total ﬂux of the bioluminescence. Note that all the pictures are shown in a
cent signals following i.c.v or i.p. infection were quantiﬁed over regions of interest from the
vivo bioluminescence imaging of the isolated organs. On day 8, anatomically distinct tissues
to ex vivo imaging. The corresponding signals from these tissues are shown in the graph. (E
by real-time PCR and RT-PCR, respectively. The brain tissue of a mock-infected mouse wasabdomen, while the luciferase signals of M3FL via i.n. inoculation
were located in the nose, spread to the lung and ﬁnally to the spleen
(Hwang et al., 2008; Milho et al., 2009). Following i.c.v. or i.p. inocu-
lation of M3FL, all the infected mice showed similar spatial and tem-
poral progression of the luciferase signals with small variations in
intensity; representative images of an i.c.v.- and an i.p.-infected
mouse are shown in Fig. 1. In the i.c.v. infected mice, a bioluminescent
signal was visible in the head area, and the signal peaked on days 3–5
and became undetectable by day 8 (Figs. 1A and B). Interestingly, a
strong signal was detected in the abdominal area on day 5. Total sig-
nals from the abdominal area on day 5 were comparable to those
from the head area on day 3 (Fig. 1B).C
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=4) were infected via i.c.v. inoculation with 8800 pfu of M3FL and then imaged on the
site of inoculation and for the spatiotemporal progression of virus replication. The scale
single scale bar. D: dorsal, L: lateral, and V: ventral positions. (B) The total biolumines-
head area in a dorsal position or the abdominal area in a lateral position. (C and D) Ex
from the brain and the abdominal area of the infected mice were isolated and subjected
and F) The harvested tissues were analyzed for viral genome loads and gene expression
used as a negative control.
25H.-R. Kang et al. / Virology 423 (2012) 23–29Ex vivo imaging of the harvested tissues at day 8 showed virus rep-
lication widespread from the site of inoculation (the left hemisphere)
to other brain areas. In addition, the spleen showed the strongest sig-
nal among abdominal tissues, suggesting it as a major source of the
luciferase signals from the abdominal area (Figs. 1C and D). The
viral genome was detected from the organs, conﬁrming that the lucif-
erase signals truly reﬂect the presence of replicating viruses and the
intensity of the luciferase signals correlated with the copy numbers
(Figs. 1E and F). The ORF57 viral lytic transcript was also detected
in these tissues, indicating ongoing lytic replication (Fig. 1F). Our re-
sults demonstrate that MHV-68 underwent lytic replication in the
brain and spread systemically to abdominal tissues of mice that sur-
vived CNS infection.
Kinetics of MHV-68 systemic spread from the brain
To conﬁrm our previous observation and to study the kinetics of
the systemic progression of the virus from the brain, we infected
mice with a lower dose of M3FL (550 pfu) via i.c.v. (n=9) or i.p.
(n=6) injection and analyzed the temporal and spatial progression
of MHV-68 replication from day 1 to day 11 (Fig. 2A). The luciferase
signals from the head area were detected ﬁrst to high levels, followed
by the signals from the abdominal area of the i.c.v.-infected mice.
These replicating signals peaked on day 5 and became subdued by
day 11 in both the head and the abdominal areas (Fig. 2A). The organs
were harvested at 5, 7, and 11 days after infection and analyzed for
the viral genome and gene expression. In the brains of the i.c.v.-
infected mice, the viral genome and the viral lytic transcripts wereOR
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Fig. 2. In vivo kinetics of M3FL systemic spread following i.c.v. inoculation. (A) Mice were in
scribed in Fig. 1. (B) After bioluminescence imaging, three i.c.v.-infected or two i.p.-infected
were analyzed by real-time PCR. DNA samples from each organ of the infected mice (n=4)
viation. The dotted line indicates the detection limit as measured in the mock samples. (C) T
of viral gene expression for RTA, an immediate early gene, and ORF57, an early gene are sho
scriptase (−) are shown as negative controls. Arrows indicate ORF57-speciﬁc transcript onthe most abundant on day 5, but gradually decreased over time
(Figs. 2B and C). Although the viral transcripts almost disappeared
on day 11, the viral genome in the brain of the i.c.v.-infected mice
remained to the levels comparable to that in the spleen of the i.p.-
infected. In the spleens, both the viral genome and the transcripts
from i.c.v.-infected mice increased to the levels similar to those
from i.p.-infected mice until day 11. The lung tissues from the i.c.v.-
infected mice were also positive for viral genome and transcripts on
day 5. The viral genome in the lung was sustained until day 11, albeit
lower in the copy number than other tissues, whereas the transcripts
became undetectable. Similar results were obtained from an indepen-
dent experiment of M3FL infection via i.c.v. (n=10) or i.p. (n=2)
followed by realtime monitoring at days 1, 3, 5, 8, and 10 (data not
shown). These results conﬁrm our initial observation that MHV-68
spreads systemically from the central nervous system and suggest
that the brain as well as the spleen may become a site of viral persis-
tency following infection via the brain.
Persistent infection of MHV-68 following inoculation in the brain
Next, we investigated whether the systemic spread of MHV-68
from the brain leads to the establishment of genuine latent infection
in the spleen. Since M3FL was shown to reduce latency in the spleen
(Hwang et al., 2008), the wild-type MHV-68 (550 pfu) were inoculat-
ed i.c.v. or i.p. (n=4 each) into mice, and the spleens were harvested
at the peak of latency (day 14). Compared with the spleens from
mock–infected mice (n=3), the spleens from both i.c.v.- and i.p.-
infected mice manifested splenomegaly, a typical symptom followingICV IP
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fected with 550 pfu of M3FL via i.c.v. (n=9) or i.p. (n=6) injection and imaged as de-
mice were sacriﬁced at days 5, 7, and 11, and viral genome loads in the isolated organs
were analyzed in triplicate and the average copy number is shown with standard de-
otal RNAs from the harvested organs were subjected to RT-PCR. Representative pictures
wn, in addition to β-actin as a loading control. Samples prepared without reverse tran-
day 5.
26 H.-R. Kang et al. / Virology 423 (2012) 23–29gammaherpesvirus infection (Fig. 3A). The viral genome loads were
equivalent between two groups of mice (Fig. 3B). The frequency of
reactivating viruses in the spleen at day 14 was also similar regardless
of inoculation routes (Fig. 3C). Our results indicate that the wild-type
MHV-68 as well as the M3FL virus in the brain can spread systemical-
ly and establish latent infection in the spleen, thereby contributing to
persistent infection in the host.In vivo reactivation of latent MHV-68 from the brain and the spleen
While our results clearly demonstrate that the spleen serves as a
latent reservoir of MHV-68 following CNS infection, it is worth inves-
tigating whether the virus can persist inside the brain. Terry et al.
showed that implantation of infected glial cells into the striatum
under the antiviral treatment led to viral persistency in the brain as
long as 12 months (Terry et al., 2000). Since the level of viral persis-
tency may be quite low in the brain, we induced reactivation from la-
tent MHV-68 in the M3FL-infected mice with cyclosporin A (CsA), an
immunosuppressive drug, as previously shown (Hwang et al., 2008).
Mice previously infected with M3FL (550 pfu) via either i.c.v. (n=4)
or i.p. (n=7) were administered with CsA every 2–3 days, starting
from day 37 post-infection when the luciferase signals were unde-
tectable. Although the signals from reactivated viruses were generally
lower than those during acute infection, the luciferase signals were
predominantly detected in the abdominal area of i.p.-infected mice
and in the head area of i.c.v.-infected mice during the monitoringA
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Fig. 3. Latency in the spleen after MHV-68 infection in the brain. Mice were inoculated
i.c.v. (n=4) or i.p. (n=4) with the wild-type MHV-68 (550 pfu), and the spleens were
harvested at day 14. Mock infection (n=3) was used as a control. (A) Splenomegaly in
the infected mice. The spleen from each mouse was weighed. Error bars indicate S.D.
Asterisks indicate signiﬁcant difference (pb0.05) as determined by student t-test. (B)
Viral genome loads in the spleen. The copy numbers of viral genome from the spleens
of infected individual mice (n=4) or mock-infection (n=3) were measured in tripli-
cates by using real-time PCR. (pb0.05) (C) Latency in the infected mice. The frequency
of reactivating viruses in the spleen at day 14 was measured by ex vivo reactivation
limiting dilution assays of the splenocytes. No infectious preformed lytic virus was
detected from the splenocytes. Error bars indicate S.E.M.period (Fig. 4A). To further conﬁrm the sites of reactivation, ex vivo
imaging of the harvested organs was conducted. The luciferase signals
were detectable from the brain and the spleen of the i.c.v.-infected
mice and from the spleen of the i.p.-infected (Fig. 4B). To conﬁrm
that the luciferase signals were due to viral reactivation, we examined
viral genome loads and lytic viral transcript. The viral genome was
positive and correlated with the luciferase signals in both tissues of
the i.c.v.-infected mice (Fig. 4C). The viral lytic transcript was also
positive in the brain (Fig. 4D). These results suggest that MHV-68
may persist inside the brain following infection in the CNS and can
be reactivated by immunosuppression in the host.
Discussion
We have used a recombinant MHV-68 expressing luciferase
(M3FL) to study anatomical sites and kinetics of in vivo virus replica-
tion upon CNS infection and further supported the bioluminescence
imaging results with molecular detection of viral genome and tran-
scripts from the isolated organs. Our results conﬁrmed that replica-
tion kinetics of M3FL was consistent with that of a recombinant
MHV-68 expressing β-galactosidase (MHV-68/LacZ) following infec-
tion via the brain (Cho et al., 2009) and that the luciferase signals in
mice infected with M3FL were correlated with the presence of the
viral genome and viral transcripts (Hwang et al., 2008). Notably, sys-
temic spread of M3FL from the brain to the spleen and reactivation of
M3FL in the brain and the spleen were revealed by in vivo and ex vivo
bioluminescence imaging, suggesting that the brain may serve as a
persistent reservoir of MHV-68 following CNS infection. These results
also reinforce the notion that the bioluminescence optical imaging
may serve as a useful tool to non-invasively monitor viral lytic repli-
cation in vivo.
Systemic spread of MHV-68 from the brain
Our previous study showed that most mice at 9 to 10 weeks of age
survived following CNS infection of MHV-68/LacZ (Cho et al., 2009).
The MHV-68/LacZ virus productively replicated and spread within
the brain tissues, but viral genome and gene expression seemed to
disappear around 10–11 days post-infection. Given the persistent na-
ture of herpesvirus infection, we investigated where the virus can
persist in the host upon cerebral infection. Our results indicate that
the virus systemically spread and established latency in the spleen,
a typical site for MHV-68 viral latency. Since all infection routes tested
so far with MHV-68 lead to latency in the spleen, it will be interesting
to investigate what mediates such systemic spread. Hematogenous
spread from the brain tissues may be a reasonable possibility, consid-
ering B cells are a known target for MHV-68 infection. Alternatively,
systemic infection may occur due to direct seeding of the virus into
the bloodstream during inoculation in the brain. Although we do
not rule out the latter possibility, it seems less likely because viral
replication in the spleen was generally delayed and not detected
until it reached the peak in the brain (Figs. 1B and 2A). Since the
viral spread from the site of inoculation to the sites of replication or
latency is poorly understood in MHV-68 infection via any routes of in-
oculation, the bioluminescence imaging technique may serve as an
important tool to dissect the viral spread in vivo.
Persistent infection of MHV-68 following CNS infection
MHV-68 does not generally invade the CNS from the periphery in
immunocompetent mice (Terry et al., 2000). Despite this, the virus
can reach the brain under certain conditions: intranasal infection of
the virus can proceed to the central nervous system of the wild-
type C57BL/6J mice (Flano et al., 2003), newborn BALB/c mice
(Hausler et al., 2005), and mice deﬁcient in the type I interferon re-
ceptor (IFN-α/β R−/−) (Terry et al., 2000). In addition, a recombinant
Cyclosporin A treatment (50mg/kg)
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Fig. 4. In vivo reactivation of latent M3FL from the brain and the spleen after CNS infection. Approximately 5 weeks after i.c.v. or i.p. infection of M3FL when the signiﬁcant biolu-
minescent signals were not detected, the mice were intraperitoneally treated with CsA (50 mg/kg) as indicated in the upper panel. (A) Bioluminescent images were taken at the
indicated dates and representative pictures are shown from an i.c.v.- or an i.p.-infected mouse. The luciferase signals of the i.c.v.-infected mouse were detected from the head area at
day 48, while those of i.p.-infected mouse were localized in the abdominal area. (B) Ex vivo bioluminescence imaging of the isolated organs. On day 48, anatomically distinct tissues
from the brain and the spleen of the infected mice were isolated and subjected to ex vivo imaging. (C and D) The harvested tissues were analyzed for viral genome loads (C) and
gene expression (D) by real-time PCR and RT-PCR, respectively. The dotted line indicates the detection limit as measured in the mock samples. Asterisks indicate signiﬁcant differ-
ence (pb0.05, student t-test). The copy number of viral genome in the brain of i.p. infection is not signiﬁcantly different from that of mock-infection. The sample synthesized with-
out reverse transcriptase (−RT) was used as a negative control.
27H.-R. Kang et al. / Virology 423 (2012) 23–29MHV-68 virus constitutively expressing RTA in the replacement of the
latent locus replicated to high titers in normal BALB/c mice and often
progressed to the brain (Jia et al., 2010). These results suggest that
viral neuroinvasiveness may be tightly controlled by the balance be-
tween host immune response and viral virulence. Because there is a
long-standing association of EBV with various neurological diseases, it
is interesting to examinewhether the brain can be a site for viral persis-
tency once the virus gains access to the brain. As abovementioned, how-
ever, it is experimentally challenging to mimic cerebral infection of
human gammaherpesviruses from the periphery, unless immunocom-
promised hosts such as neonates or interferon α/β R−/− mice are
infected. Even in these models, viral persistency in the brain cannot be
addressed because the infected mice succumbed to deaths within5–14 days. Therefore, in this report, we directly introduced the virus
into the brain of 9–10 week-old mice that can survive following CNS
infection.
Reactivation of the latent virus is thought to be an important
mechanism to replenish and maintain the latent pool of gammaher-
pesviruses in the host. Spontaneous and sporadic reactivation of
MHV-68 from latency was detected in the wild-type mice and further
induced by the treatment with CsA, an immunosuppressive drug
(Hwang et al., 2008). The luciferase signals from reactivated viruses
were generally lower than those from acute infection, which may re-
ﬂect the reduced level of M3FL latency (Hwang et al., 2008). It was
also found that the luciferase signals were predominantly found in
the head area rather than in the abdominal area of the i.c.v.-infected
28 H.-R. Kang et al. / Virology 423 (2012) 23–29mice, although the luciferase signals from ex vivo imaging and molec-
ular detection of viral genome and lytic transcript clearly indicated
the presence of reactivated viruses in the spleen following i.c.v. inoc-
ulation (Fig. 4). Consistent with this, the previous report showed that
the extent and the major site of reactivation varied depending
on routes of infection and generally correspond to the primary site
of inoculation upon the treatment of CsA; for example, the spleen
for the i.p., the lung for the i.n., and salivary gland for the oral route
(Hwang et al., 2008). However, all of these routes were shown to ad-
ditionally harbor reactivated viruses in the spleen as detected in
ex vivo imaging and RT-PCR. Therefore, ex vivo imaging and other mo-
lecular approaches would be useful in consolidating a conclusion
from in vivo imaging.
Although our experimental system has limitation, our in vivo reac-
tivation results suggest viral persistency in the brain; reactivated
M3FL viruses were detected in the brain tissues of the i.c.v.-injected
mice, as measured by the luciferase activity, viral genomic DNA, and
lytic transcript (Fig. 4). Alternatively, the reactivated viruses originat-
ed from the spleen or latently-infected B cells may have reached the
brain under the immunosuppressive condition. Although the blood–
brain barrier (BBB) is highly restricted to CsA, the BBB permeability
can be induced by CsA (Dohgu et al., 2010). However, no signal
was detected in the head area among the i.p.-infected mice (Fig. 4)
or i.n.-infected ones treated with CsA (Hwang et al., 2008), suggesting
that not all reactivated viruses can reach the brain from the
periphery.
These results may add relevance to the clinical situations such as
cerebral infection of Epstein–Barr virus as it may often occur in im-
munocompromised hosts; EBV is strongly associated with primary
CNS lymphoma in immunodeﬁcient patients (Hoover et al., 2004).
In addition, EBV reactivation has been linked to the disease activity
in patients with multiple sclerosis, an inﬂammatory disease of the
CNS (Wandinger et al., 2000) and the epidemiological data are com-
pelling to support the association of EBV with MS (Ascherio and
Munger, 2007; Zaadstra et al., 2008). A recent study reported that
dysregulated EBV infection was found in the brain of the MS patients
(Seraﬁni et al., 2007), further suggesting a critical role of EBV as a
pathogenic feature or an etiological environmental factor in MS. Tak-
ing this into consideration, it will be interesting to elucidate which
types of the cells in the brain may harbor reactivatable viral genomes
following the CNS infection in our study. Neuronal cells may serve as
a persistency reservoir as MHV-68 replicates and spreads in the brain
via neuronal tracks during the acute infection (Cho et al., 2009). Given
the nature of gammaherpesviruses, CNS-resident myeloid cells or
lymphoid cells can be plausible candidates as well.
Taken together, our results highlight a possible role of the brain as
a site for viral persistency following CNS infection of gammaherpes-
viruses and the usefulness of an in vivo and ex vivo bioluminescence
imaging technique in tracking down viral replication.
Materials and methods
Cells, viruses, and plaque assays
Vero (green monkey kidney cell line) and BHK21 (baby hamster kid-
ney ﬁbroblast cell line) cells were cultured in complete Dulbesco's mod-
iﬁed Eagle's medium containing 10% fetal bovine serum (HyClone) and
supplementedwith penicillin and streptomycin (10 units/ml) (HyClone),
while NIH3T3 cells were cultured with 10% bovine calf serum (Gibco).
MHV-68 virus was obtained originally from the American Type Culture
Collection (VR1465). Working virus stocks were grown by infecting
NIH3T3 cells at a multiplicity of infection (MOI) of 0.05 pfu/cell. The
M3FL recombinant virus expressing ﬁreﬂy luciferase was constructed as
previously described (Hwang et al., 2008). Viral titers were determined
by plaque assay using Vero cells overlaid with 1%methylcellulose in nor-
mal growth media. After 5 days of infection, the cells were ﬁxed andstained with 2% crystal violet in 20% ethanol. Plaques were then counted
to determine the titers.Mice experiments
BALB/c mice at 8–9 weeks of age were purchased from Samtako
(South Korea) and maintained for 1 week before the experiment.
The animals were fed a commercial diet and water ad libitum under
controlled temperature, humidity, and lighting conditions. Proce-
dures involving animals and their care were conducted in accord
with institutional guidelines that comply with international laws
and policies (NIH Guide for the Care and Use of Laboratory Animals,
NIH Publication No.85-23, 1996). Mice at 9–10 weeks of age were
intracerebroventricularly (i.c.v.) injected in the left hemisphere of
the brain with 11 μl of either M3FL virus (8800 or 550 pfu) or
serum-free DMEM media. This procedure was performed using a
Hamilton syringe following anesthesia with an intraperitoneal injec-
tion of 2,2,2-tribromoethanol in 2-methyl-2-butanol (Sigma-Aldrich;
250 mg/kg). The same titer of M3FL was intraperitoneally injected in
a volume of 200 μl as a control into a new set of mice. The survival
rate of 9–10 week-old mice following i.c.v. inoculation was ca. 80%
in these experiments, similar to our previous report (Cho et al., 2009).
To measure the latent virus in the spleen, ex vivo reactivation with
limiting dilution assays was performed as previously described with
slight modiﬁcation (Jia et al., 2010). Brieﬂy, Vero cells (1×103/well)
were seeded in 96-well plates. Serial twofold dilutions of puriﬁed
splenocytes, starting from 106 cells/well were plated and co-
cultivated with monolayer Vero cells with 24 wells per dilution.
After 7 days, each well was scored for cytopathic effects, and the per-
centage of wells showing cytopathic effects was calculated and plot-
ted with the number of splenocytes. As a control, the presence of
preformed viruses in the splenocytes was also examined by incubat-
ing Vero cells with the splenocytes following three rounds of freezing
and thawing. No infectious preformed viruses were detected. To reac-
tivate latent M3FL in vivo, CsA (50 mg/ kg) was injected intraperito-
neally into the infected mice every 2–3 days as indicated.Bioluminescence optical imaging
Bioluminescence imaging ofM3FL replication inmicewas performed
using the in vivo imaging system (IVIS 200; Xenogen Corp., Alamanda,
Calif)with a cooled charge-coupled-device (CCD) camera. At the indicat-
ed time-points, the infected mice were intranasally anesthetized with
isoﬂurane and intraperitoneally administered with D-lucferin (3 mg/
mouse). The substrate for the ﬁreﬂy luciferase, D-lucferin, is known to
cross most cellular membranes including the intact blood–brain barrier,
allowing the detection of the signal in most anatomic sites (Choy et al.,
2003a, 3003b). To detect the signals, images were taken from dorsal,
ventral, and lateral sides of the bodies 10 min after administration of
the substrate. Total ﬂux in the region of interest (ROI) was analyzed by
the image processing software, LivingImage (Xenogen). After the ﬁrst
bioluminescence signals were waned, the infected mice were injected
again with D-luciferin (3 mg/mouse) and the harvested organs were
subjected to ex vivo bioluminescence imaging.Viral RNA isolation and RT-PCR analysis
Total RNAs were extracted from tissues using TRI reagents (Molecu-
lar Research Center) according to the manufacturer's instructions and
further cleanedwith RNeasymini kit (Qiagen). The cDNAswere synthe-
sized using a RevertAid First strand cDNA synthesis (Fementas, South
Korea) with random hexamers. The synthesized cDNAs were subjected
to RT-PCR analysis using cellular β-actin-speciﬁc primers or viral
transcript-speciﬁc primers for RTA and ORF57 (Lee et al., 2007).
29H.-R. Kang et al. / Virology 423 (2012) 23–29Viral DNA isolation and real-time PCR analysis
Genomic DNAs, including viral DNAs from cells or tissues, were
isolated using DNeasy kit (Qiagen) (Song et al., 2005). Real-time
PCR of genomic DNA (200 ng) was performed in triplicate on an iCy-
cler (Bio-Rad) as a 20-μl reaction mixture using SYBR green and viral
genome-speciﬁc primers for the ORF 56 locus (nt 75,598–75,783)
(Lee et al., 2007). The BAC plasmid containing the MHV-68 genome
was used as standards to calculate the copy number. Real-time PCR
was run at 50 °C for 2 min and 45 cycles at 95 °C for 10 s, 58 °C for
15 s, and 72 °C for 20 s, followed by melting curve analysis. The re-
sults were analyzed according to the manufacturer's instructions.Acknowledgments
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